



Attorney Docket No.: 6460.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Balschmidt et al.

Serial No.: 10/602,456

Group Art Unit: To be assigned

Filed: June 23, 2003

Examiner: To be assigned

For: Use of Dimethyl Sulfone as Isotonicity Agent

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (10)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on August 28, 2003

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)

PATENT



Attorney Docket No.: 6460.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Balschmidt et al.

Application No.: 10/602,456

Group Art Unit: To be assigned

Filed: June 23, 2003

Examiner: To be assigned

For: Use of Dimethyl Sulfone as Isotonicity Agent

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. U.S. Patent no. 4,296,130
2. U.S. Patent no. 4,477,469
3. U.S. Patent no. 4,514,421

4. U.S. Patent no. 4,559,329
5. U.S. Patent no. 4,568,547
6. U.S. Patent no. 4,616,039
7. U.S. Patent no. 4,863,748
8. U.S. Patent no. 4,973,605
9. Canadian Patent no. CA1319107
10. WO 01/26642

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: August 28, 2003

Respectfully submitted,



Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

